within Pharmacolibrary.Drugs.ATC.V;

model V03AE08
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.01,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 630 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>V03AE08</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Ferric citrate is an iron-based phosphate binder used to control serum phosphorus levels in patients with chronic kidney disease on dialysis. It also increases iron stores and helps to manage anemia. It is approved for clinical use in the US and other countries.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic models for systemic absorption are available, as ferric citrate acts locally in the gastrointestinal tract. Minimal systemic absorption occurs; the drug acts by binding dietary phosphate in the GI tract of adult CKD patients.</p><h4>References</h4><ol><li><p>Nakanishi, T, et al., &amp; Kuragano, T (2016). Novel iron-containing phosphate binders and anemia treatment in CKD: oral iron intake revisited. <i>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</i> 31(10) 1588–1594. DOI:<a href=\"https://doi.org/10.1093/ndt/gfv268\">10.1093/ndt/gfv268</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26142396/\">https://pubmed.ncbi.nlm.nih.gov/26142396</a></p></li><li><p>Floege, J, et al., &amp; Sprague, SM (2020). Iron kinetics following treatment with sucroferric oxyhydroxide or ferric citrate in healthy rats and models of anaemia, iron overload or inflammation. <i>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</i> 35(6) 946–954. DOI:<a href=\"https://doi.org/10.1093/ndt/gfaa030\">10.1093/ndt/gfaa030</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32259248/\">https://pubmed.ncbi.nlm.nih.gov/32259248</a></p></li><li><p>Paulson, SK, et al., &amp; Chavan, A (2022). Effect of Phosphate Binders and a Dietary Iron Supplement on the Pharmacokinetics of a Single Dose of Vadadustat in Healthy Adults. <i>Clinical pharmacology in drug development</i> 11(4) 475–485. DOI:<a href=\"https://doi.org/10.1002/cpdd.1033\">10.1002/cpdd.1033</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35172045/\">https://pubmed.ncbi.nlm.nih.gov/35172045</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end V03AE08;
